Lilium rose 3.6% before the market opened and Swiss nickel refining company KL1 will invest in building a new plant in France.

Related posts

• JP Morgan strategist Kolanovic continues to bet on U.S. stocks and becomes Wall Street’s only remaining big short

  There is only one big short left among Wall Street’s stock market opinions. After Morgan Stanley’s Mike Wilson defected on Monday, only JPMorgan Chase’s Marko Kolanovic still maintains his pessimistic view on U.S. stocks.

  US Stocks Focus May 21, 2024

• Sensex, Nifty open marginally higher; PSU bank stocks advance

  BSE Sensex rose by 103.62 pts or 0.14 per cent at 73,208.23 as of 9.20 am, and Nifty 50 was up 43.85 pts or 0.2 per cent at 22,261.70.

  US Stocks Focus May 15, 2024

• Manali Petrochemicals subsidiary appoints distributor for silicone oils in UK, Ireland

  Manali Petrochemicals Ltd’s (MPL) subsidiary PennWhite Limited, UK, has announced a long-term agreement with KRAHN UK Ltd for the distribution of silicone oil in the UK and Ireland.

  US Stocks Focus May 15, 2024

• Burman Family-controlled entities make insider trading complaint against Religare Chief Saluja

  The Burman Family, promoters of Dabur Group and single-largest shareholder in Religare Enterprises Ltd (REL), have approached SEBI accusing REL Chairperson Rashmi Saluja of yet another breach of the market regulator’s insider trading norms.

  US Stocks Focus May 24, 2024

• New tax treatment.Cash-rich companies expected to prefer dividends after buyback tax removal

  Budget 2024 proposal to scrap buyback tax for companies and in turn tax the payouts as ‘deemed dividends’ at the hands of recipients is set to reduce interests in share repurchase programmes among promoters, say tax experts.

  US Stocks Focus July 28, 2024

• The vaccine market is turbulent, and Zhifei Biotech’s “big brother” status is difficult to maintain

  For stock trading, please read Jin Qilin analyst research reports. They are authoritative, professional, timely and comprehensive, helping you to tap potential theme opportunities! Source: Financial Investment News Financial Investment News reporter Chen Yuhe After Zhifei Biotechnology (300122), the “vaccine brother”, released its 2023 annual report, its stock price continued to fall. Some market participants attributed its falling stock price to its high reliance on foreign supplies. Business is linked to the gradually revealed decline in performance. In recent years, the vaccine market has been changing. On the one hand, the once \”hot-selling\” nine-price HPV vaccine is no longer hard to find. On the other hand, various good news about the domestically produced nine-price HPV vaccine continue to spread, attracting a lot of attention. Institutions pay great attention to its listing process. Zhifei Bio\’s growth capability indicators Zhi Fei Bio\’s stock price continues to fall. The annual report shows that in 2023, Zhi Fei Bio\’s operating income was 52.918 billion yuan, a year-on-year increase of 38.3%; it achieved net profit attributable to the parent company of 8.07 billion yuan, a…

  US Stocks Focus April 25, 2024